首页> 美国卫生研究院文献>Oncotarget >Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy
【2h】

Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy

机译:II和III期非小细胞肺癌患者接受辅助化疗的程序性细胞死亡配体1表达和免疫分数

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Programmed cell death 1 (PD-1) receptor–ligand interaction is a major pathway that is often hijacked by tumors to suppress immune control. Immunoscore (IS), a combinational index of CD3 and CD8 tumor-infiltrating lymphocyte (TIL) density in the tumor’s center and invasive margin, is a new prognostic tool suggested to be superior to conventional tumor-staging methods in various tumors. This retrospective study aimed to investigate the prevalence and prognostic roles of PD-ligand 1 (PD-L1) expression and IS in non-small cell lung cancer (NSCLC) patients receiving adjuvant chemotherapy. PD-L1 expression and TIL density were evaluated by immunohistochemical analysis in 36 patients with stage II and III NSCLC. Tumors with staining in over 1% of their cells were scored as positive for PD-L1 expression, and we determined the median number of CD3- and CD8-positive TILs as the cutoff point for TIL density. To determine IS, each patient was given a binary score (0 for low and 1 for high) for CD3 and CD8 density in both the tumor center and invasive margin region. PD-L1 expression in tumor cells was observed in 61.1% (22/36) of patients. PD-L1 expression was significantly associated with high IS, and highest IS tended to have a favorable disease-free survival.
机译:程序性细胞死亡1(PD-1)受体与配体的相互作用是肿瘤经常劫持以抑制免疫控制的主要途径。 Immunoscore(IS)是位于肿瘤中心和浸润边缘的CD3和CD8肿瘤浸润淋巴细胞(TIL)密度的综合指标,是一种新的预后工具,被认为优于各种肿瘤的常规肿瘤分期方法。这项回顾性研究旨在调查PD-配体1(PD-L1)表达和IS在非小细胞肺癌(NSCLC)接受辅助化疗的患者中的患病率和预后作用。通过免疫组化分析评估了36例II期和III期NSCLC患者的PD-L1表达和TIL密度。超过1%细胞染色的肿瘤被评为PD-L1表达阳性,我们将CD3-和CD8阳性TIL的中位数确定为TIL密度的临界点。为了确定IS,每位患者在肿瘤中心和浸润边缘区域均获得了CD3和CD8密度的二进制评分(低分0分,高分1分)。在61.1%(22/36)的患者中观察到肿瘤细胞中PD-L1的表达。 PD-L1表达与高IS显着相关,而最高IS倾向于具有良好的无病生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号